Brilinta, Brilique(ticagrelor)
Brilinta, Brilique, Ticagrelor (ticagrelor) is a small molecule pharmaceutical. Ticagrelor was first approved as Brilique on 2010-12-03. It has been approved in Europe to treat acute coronary syndrome and peripheral vascular diseases. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target equilibrative nucleoside transporter 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Brilinta, Ticagrelor (discontinued: Ticagrelor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ticagrelor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BRILINTA | AstraZeneca | N-022433 RX | 2011-07-20 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| brilinta | New Drug Application | 2024-08-28 |
| ticagrelor | ANDA | 2020-08-20 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TICAGRELOR, BRILINTA, ASTRAZENECA | |||
| 2025-11-09 | PED | ||
| 2025-05-09 | M-283 | ||
| 2024-05-05 | PED | ||
| 2023-11-05 | I-848 | ||
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
579 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 5 | 9 | 21 | 69 | 59 | 161 |
| Coronary artery disease | D003324 | — | I25.1 | 4 | 16 | 20 | 73 | 38 | 145 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 3 | 6 | 20 | 64 | 31 | 122 |
| Infarction | D007238 | EFO_0009463 | — | 3 | 6 | 18 | 62 | 32 | 119 |
| Syndrome | D013577 | — | — | — | 4 | 14 | 45 | 30 | 92 |
| Coronary disease | D003327 | — | — | 1 | 12 | 9 | 37 | 21 | 76 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | 13 | 8 | 38 | 20 | 75 |
| St elevation myocardial infarction | D000072657 | — | — | 1 | 2 | 10 | 33 | 8 | 54 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 2 | 22 | 4 | 6 | 33 |
| Ischemia | D007511 | EFO_0000556 | — | 2 | 6 | 16 | 10 | 5 | 33 |
Show 75 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 2 | 6 | — | 1 | 7 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 2 | 2 | — | — | 6 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 1 | 1 | — | — | 3 |
| Pharmacological phenomena | D000069437 | — | — | — | — | 1 | — | 2 | 3 |
| Chronic limb-threatening ischemia | D000089802 | — | — | 1 | 2 | 1 | — | — | 2 |
| Death | D003643 | PATO_0001422 | — | — | — | 1 | — | 1 | 2 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | 1 | — | 1 | 2 |
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | — | — | 1 | — | 1 | 2 |
| Bartter syndrome | D001477 | Orphanet_112 | E26.81 | — | — | 1 | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carotid stenosis | D016893 | — | — | 1 | 1 | — | — | 3 | 5 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | 1 | — | — | 2 | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 2 | — | — | — | 2 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 2 | — | — | — | 2 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 2 | — | — | — | 2 |
| Arteriovenous fistula | D001164 | — | Q27.3 | 1 | 1 | — | — | 1 | 2 |
| Fistula | D005402 | — | — | 1 | 1 | — | — | 1 | 2 |
| Reperfusion injury | D015427 | — | — | 1 | 1 | — | — | — | 1 |
| Critical illness | D016638 | — | — | — | 1 | — | — | — | 1 |
| Vascular patency | D014654 | — | — | 1 | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | 1 | 4 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | 1 | — | — | — | — | 1 |
| Healthcare-associated pneumonia | D000077299 | — | — | 1 | — | — | — | — | 1 |
| Lung injury | D055370 | — | S27.30 | 1 | — | — | — | — | 1 |
| Blood flow velocity | D001783 | — | — | 1 | — | — | — | — | 1 |
| Coronary circulation | D003326 | — | — | 1 | — | — | — | — | 1 |
| Gout | D006073 | EFO_0004274 | M10 | 1 | — | — | — | — | 1 |
| Optical coherence tomography | D041623 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | — | — | 4 | 4 |
| Pulmonary embolism | D011655 | HP_0002204 | I26 | — | — | — | — | 4 | 4 |
| Vertebrobasilar insufficiency | D014715 | EFO_1001449 | G45.0 | — | — | — | — | 3 | 3 |
| Surgical blood loss | D016063 | — | — | — | — | — | — | 2 | 2 |
| Blood platelet disorders | D001791 | — | — | — | — | — | — | 2 | 2 |
| Pharmacogenomic testing | D000071185 | — | — | — | — | — | — | 2 | 2 |
| Pneumocephalus | D011007 | EFO_1001398 | — | — | — | — | — | 2 | 2 |
| Heart valve prosthesis | D006350 | EFO_0003906 | — | — | — | — | — | 1 | 1 |
| Coronary occlusion | D054059 | — | I21 | — | — | — | — | 1 | 1 |
| Cerebral amyloid angiopathy | D016657 | EFO_0006790 | I68.0 | — | — | — | — | 1 | 1 |
Show 37 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ticagrelor |
| INN | ticagrelor |
| Description | Ticagrelor is a triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome. It has a role as a platelet aggregation inhibitor and a P2Y12 receptor antagonist. It is a member of triazolopyrimidines, an organofluorine compound, an aryl sulfide, a secondary amino compound and a hydroxyether. |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 274693-27-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL398435 |
| ChEBI ID | 68558 |
| PubChem CID | 9871419 |
| DrugBank | DB08816 |
| UNII ID | GLH0314RVC (ChemIDplus, GSRS) |
Target
Agency Approved
P2RY12
P2RY12
Organism
Homo sapiens
Gene name
P2RY12
Gene synonyms
HORK3
NCBI Gene ID
Protein name
P2Y purinoceptor 12
Protein synonyms
ADP-glucose receptor, ADPG-R, G-protein coupled receptor SP1999, Gi-coupled ADP receptor HORK3, P2T(AC), P2Y(AC), P2Y(ADP), P2Y(cyc), P2Y12 platelet ADP receptor, purinergic receptor P2RY12, purinergic receptor P2Y, G-protein coupled, 12, putative G-protein coupled receptor, SP1999
Uniprot ID
Mouse ortholog
P2ry12 (70839)
P2Y purinoceptor 12 (Q9CPV9)
Alternate
SLC29A1
SLC29A1
Organism
Homo sapiens
Gene name
SLC29A1
Gene synonyms
ENT1
NCBI Gene ID
Protein name
equilibrative nucleoside transporter 1
Protein synonyms
Equilibrative NBMPR-sensitive nucleoside transporter, equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter, Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter, es nucleoside transporter, Nucleoside transporter, es-type, solute carrier family 29 (equilibrative nucleoside transporter), member 1, solute carrier family 29 (nucleoside transporters), member 1, Solute carrier family 29 member 1
Uniprot ID
Mouse ortholog
Slc29a1 (63959)
equilibrative nucleoside transporter 1 (Q9JIM1)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Brilinta – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ticagrelor
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,499 documents
View more details
Safety
Black-box Warning
Black-box warning for: Brilinta, Ticagrelor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,541 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use